The purpose of the study was to evaluate the effect of lisofylline (LSF) on engraftment, regimen-related toxicities (RRT), and mortality in patients undergoing allogeneic bone marrow transplantation (BMT). We performed a multicenter, randomized placebo-controlled trial in 60 patients with hematologic malignancies receiving BMT from HLA-identical sibling donors. Patients were randomized to receive either placebo, 2 mg/kg LSF or 3 mg/kg LSF every 6 h, beginning before conditioning and continuing to day 21 or hospital discharge. Treatment groups were balanced with respect to conditioning regimen and disease stage. However, significantly more patients in the 2 mg/kg LSF group were at high risk for RRT due to performance status у1, age у40 years, and prior exposure to CMV. Nausea and vomiting were the only adverse events observed in a higher proportion of LSF-treated patients that led to study withdrawal in six of 42 patients (14%). The times to neutrophil recovery to у500/l and platelet recovery (Ͼ20 000/l) were not improved by LSF treatment. Nevertheless, no patient who received treatment with 3 mg/kg LSF developed a documented infection between day 0 and 35 or had a serious or fatal infection between day 0 and 100 (P = 0.003 vs placebo for both). The day-100 survival rate was also significantly improved in the 3 mg/kg LSF group (89%), compared with either the 2 mg/kg LSF (48%) or placebo (61%) groups (log-rank test, 3 mg/kg LSF vs placebo, P = 0.026). We conclude that treatment with LSF 3 mg/kg reduced the incidence of infections and improved 100-day survival in patients receiving related-donor allogeneic bone marrow transplantation. Allogeneic bone marrow transplantation (BMT) is a potentially curative treatment for patients with hematologic malignancies, albeit with significant procedure-related morbidity and mortality. Infection, regimen-related toxicities, and graft-versus-host disease (GVHD) remain the leading causes of morbidity and mortality. A number of host-and treatment-related factors contribute to the risk of infection, including age, performance status, cytomegalovirus exposure, prolonged neutropenia, immunosuppression, and the disruption of normal barriers to bacterial translocation as a result of mucosal injury.
Allogeneic bone marrow transplantation (BMT) is a potentially curative treatment for patients with hematologic malignancies, albeit with significant procedure-related morbidity and mortality. Infection, regimen-related toxicities, and graft-versus-host disease (GVHD) remain the leading causes of morbidity and mortality. A number of host-and treatment-related factors contribute to the risk of infection, including age, performance status, cytomegalovirus exposure, prolonged neutropenia, immunosuppression, and the disruption of normal barriers to bacterial translocation as a result of mucosal injury. A variety of mediators of inflammation, including lipid peroxides such as hydroperoxyoctadecadienoic acids (HPODEs), and pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-␣), interleukin-1 beta (IL-1 ␤), and interferon gamma (IFN-␥), as well as hematopoietic inhibitory peptides such as macrophage-inhibitory factor 1-␣ and transforming growth factor-beta (TGF-␤) have been implicated in the pathogenesis of many transplant-related toxicities. By further compromising tissue integrity, increasing capillary permeability, prolonging the interval to mucosal, epithelial, and hematologic recovery, these mediators may increase the incidence of infections and the severity of GVHD. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Indeed, in granulocytopenic patients, the magnitude of the pro-inflammatory cytokine response to infection directly correlates with sepsis-related mortality, [12] [13] [14] and in the setting of allogeneic stem cell transplant, correlates with GVHD severity. 10 Abrogation of this response in neutropenic animals significantly reduces sepsis-related deaths. 15 Agents that effectively preserve mucosal barrier integrity, attenuate the inflammatory cytokine response, or shorten the duration of neutropenia therefore may significantly reduce the risk of infection and regimen-related mortality.
Lisofylline (LSF), 1-(5-R-hydroxyhexyl)-3,7-dimethylxanthine, is an enantiomerically specific methylxanthine with anti-inflammatory properties that is under development as an agent to reduce the toxicities and risk of infection associated with dose-intensive cytotoxic therapy. LSF selectively suppresses the formation of lipid peroxides induced in response to oxidative stress and/or cytotoxic injury (unpublished data). As a result, LSF suppresses activation of specific oxidatively activated signal transduction pathways and the consequent inflammatory response by suppressing induction of pro-inflammatory and growth-Bone Marrow Transplantation inhibitory cytokines such as TNF-␣, IFN-␥, and TGF-␤. [16] [17] [18] In preclinical studies, LSF protected against increased intestinal permeability to macromolecules and bacterial translocation into liver and lung following bowel ischemia and reperfusion. 19, 20 In murine models, LSF shortened the duration of myelosuppression and accelerated enteric crypt stem cell regeneration following the administration of potentially lethal doses of antineoplastic agents (unpublished data). 21 Similarly, LSF suppressed lipid peroxidation and the induction of inflammatory cytokines in response to oxidative injury or septic shock, and protected against lung injury and the attendant increase in pulmonary vascular permeability. 16, [22] [23] [24] Phase I concentration-controlled trials have demonstrated dosing requirements of 2 mg/kg or greater to achieve a plasma concentration of Ͼ10 m which is required for activity in surrogate biological assays. 25, 26 To further evaluate the clinical activity of LSF, we investigated the effects of two doses of LSF within the presumed therapeutic range in a randomized, double-blind, placebocontrolled trial in patients with hematologic malignancy undergoing human leukocyte antigen (HLA)-identical, sibling-donor, allogeneic BMT. The principal end points of this study included the effect of LSF on hematopoietic reconstitution, the incidence of infection, regimen-related toxicity, and survival.
Materials and methods

Study design
Patients with a diagnosis of a hematologic malignancy undergoing phenotypic HLA-identical, sibling-donor, allogeneic BMT were eligible for the study. The study protocol was approved by the participating institution Human Subjects Committees. Patients were randomly assigned to receive treatment with placebo or one of two dose levels of LSF (2 or 3 mg/kg). Patients were prospectively stratified only by treatment center. Study drug was administered intravenously as a 10-min intravenous (i.v.) infusion every 6 h. Two doses of the study drug were administered before initiation of the cytoreductive regimen, and treatment was continued until day 21 post-BMT or hospital discharge, whichever occurred first. The maximum number of days of LSF administration was 31 days. Peak and trough plasma levels of LSF were measured on the day of bone marrow infusion (day 0). Toxicities were assessed using the acute regimen-related toxicity scale. 27 
Patients
A total of 60 patients, age 21 to 59 years were enrolled in the study. Clinical characteristics of the study participants and conditioning regimens are summarized in Tables 1 and  2 . Patients received institutionally approved conditioning regimens consisting of chemotherapy with or without totalbody irradiation (doses ranged from 10 to 14 Gy, Table 2 ). Eighteen patients were assigned to the placebo group, 23 patients received 2 mg/kg LSF, and 19 patients were assigned to treatment with 3 mg/kg LSF. Distribution of patients according to conditioning regimen and the percentage of patients with advanced disease was approximately balanced among study groups; however, a higher proportion of patients in the LSF-treatment groups, particularly the 2 mg/kg LSF group, had a median age у40 years, SWOG PS у1, and greater number of patients with chronic myelogenous leukemia compared with the placebo group (Table 1 and 2 ). In addition, more patients in the 2 mg/kg LSF group than placebo-treated patients were CMV seropositive. When age у40 years, CMV serology, and PS у1 were evaluated across treatment groups, six of 23 patients (26%) in the 2 mg/kg LSF group had three of these adverse risk factors, compared with only one of 18 patients (6%) in the placebo group and one of 19 patients (5%) in the 3 mg/kg LSF group (P = 0.02; LSF 2 mg/kg vs placebo). Furthermore, seven patients in the 2 mg/kg LSF group had two adverse risk factors compared with only four patients in the placebo group and eight patients in the 3 mg/kg LSF group. Thus, 13 of 23 patients (56%) in the 2 mg/kg LSF group had at least two risk factors compared with five of 23 patients (28%) in the placebo group and nine of 19 patients (47%) in the 3 mg/kg LSF group.
GVHD prophylaxis and treatment
All patients received a standardized GVHD prophylaxis regimen consisting of cyclosporin A and corticosteroids. Cyclosporin A was initiated on the day before bone marrow infusion (ie, day Ϫ1) at an i.v. dosage of 1.5 mg/kg every 12 h. The dose was adjusted to maintain a trough plasma level between 250 and 400 ng/ml. Dose adjustments for nontherapeutic blood levels and/or azotemia were standardized. In the absence of acute GVHD, the dose was tapered after day 50 by decreasing the dose 5% per week relative to the starting dose. Intravenous methylprednisolone was initiated on day 7 as previously described. 28 For patients experiencing grade 2 acute GVHD, the methylprednisolone dose was increased to 2.0 mg/kg/day for 3 to 4 weeks before beginning a drug taper. For patients unresponsive to corticosteroid dose-escalation, institutional standard or experimental GVHD regimens could be initiated. Acute GVHD was graded according to standard published criteria. 29 
Supportive care
Patients with active disease or large tumor mass at the time of initiation of the conditioning regimen received allopurinol (300 mg/day) beginning before cytoreductive therapy and continuing until day Ϫ1. Patients seropositive for herpes simplex virus (HSV) or varicella-zoster received prophylactic acyclovir (250 mg/m 2 ) every 8 h beginning on the day of admission and continuing until hospital discharge. Patients seropositive for cytomegalovirus (CMV), and CMV-seronegative patients who received marrow from a CMV-seropositive donor, received prophylactic ganciclovir (5 mg/kg/day, 5 days per week) following neutrophil engraftment, and continuing until day 100 post-BMT. Intravenous immunoglobulin was administered to all CMVpositive patients (500 mg/kg/week) starting in week 1 post-BMT and continuing until day 100 post-BMT. CMVseronegative patients received CMV-seronegative blood products, irrespective of donor CMV serologic status.
All patients received prophylactic parenteral broad-spectrum antibiotics beginning the first day that the absolute neutrophil count (ANC) decreased to Ͻ500/l. Planned treatment with hematopoietic growth factors was prohibited. Thresholds for transfusions were standardized; red blood cell transfusions were given when hematocrit was Ͻ25%, and platelet transfusions were given when the platelet count was Ͻ20 000/l. All patients received prophylactic trimethoprim sulfamethoxazole (one double-strength Bone Marrow Transplantation tablet twice daily) for Pneumocystis carinii, initiated on the day of hospital admission and discontinued 1 day prior to the bone marrow infusion. Fluconazole (200 mg/day) was administered for fungal prophylaxis. Patients with persistent febrile neutropenia or documented fungal infection received amphotericin B or other antifungal agents as clinically indicated. Patients could not receive treatment with methylxanthine derivatives such as theophylline or pentoxifylline.
Definition of engraftment
Documentation of hematopoietic engraftment was based on peripheral blood counts and bone marrow aspiration. Neutrophil engraftment was defined as the first of 2 consecutive days after the neutrophil nadir when the ANC was у500/l. Platelet engraftment was defined as the first day after transplantation when the platelet count was Ͼ20 000/l without transfusion and remained above that level for 7 consecutive days without transfusions.
Definition of infection
An infectious event was defined either as the occurrence of a single positive blood culture for any bacterial or fungal organism other than coagulase-negative Staphylococcus, for which two or more positive blood cultures within a 24-h period were required, or as an infection in an organ or closed space confirmed via culture or histologic examination. All non-viral infections that occurred between day 0 and day 35 post-BMT were included in the analysis. A seri-ous infection was defined as an infectious event, as described above, associated with any of the following: documented organ involvement, grade 3 or 4 toxicity, 27 hypotension, and/or persistent positive blood cultures despite appropriate antibiotic therapy and intravenous catheter removal. Infections were scored prior to unblinding of the study by a three-member, independent expert panel and required unanimous agreement. Fatal infections were those designated by the investigator as the proximate cause of death.
Safety evaluation
Toxicities, including mucositis, were graded using the standard three-point Acute Regimen-Related Toxicity Scale. The highest score achieved between day 0 and 21 was used as the index of mucositis severity.
Statistical analyses
All efficacy analyses were done using all patients randomized to treatment (ie, the intent-to-treat population) and included data from all patients randomized to treatment and received as of January 1998. Analyses of between-group differences in demographic features and efficacy endpoints were performed non-parametrically using either the exact Wilcoxon's rank-sum test statistic or Fisher's exact test. The Cochran-Mantel-Haenszel test statistic was used for analyzing contingency tables. Comparisons of survival were analyzed using the log-rank test. 30 All statistical tests were two-sided and were not adjusted for multiple comparisons.
Results
Study drug tolerance and disposition
Forty-five of 60 (75%) randomized patients completed the double-blind treatment period to day 21 post-BMT or were discharged early, including 16 of 18 patients in the placebo group, 15 of 23 patients in the 2 mg/kg LSF group, and 14 of 19 patients in the 3 mg/kg LSF group (Table 3 ). Nine Table 3 Adverse experiences possibly or probably related to study drug number (percent) patients withdrew from study drug treatment prematurely due to adverse events (four patients in the 2 mg/kg LSF group and five patients in the 3 mg/kg LSF group). The most common adverse event was nausea and vomiting, precipitating early study withdrawal by four patients in the 2 mg/kg LSF group and two patients in the 3 mg/kg LSF group. Other adverse events limiting study drug treatment in the 3 mg/kg LSF group included weakness (one patient), vasodilatation (one patient), and seizures (one patient). No patients treated with placebo terminated study drug due to adverse events. Four patients received an incomplete course of study drug due to early death (one placebo-treated patient and three patients receiving 2 mg/kg LSF). Study drug was withdrawn in one placebo-treated patient because of patient request and in one patient receiving 2 mg/kg LSF because of initiation of growth factor therapy for a serious infection. Adverse events more commonly reported in either of the LSF treatment groups than the placebo group included headache, abdominal pain, nausea and vomiting (Table 3) . When evaluated by maximum toxicity scores, skin rashes, and diarrhea occurred at a lower frequency during study drug treatment in patients who received 3 mg/kg LSF than in placebo-treated patients (data not shown).
Patients receiving 3 mg/kg LSF had higher C max plasma levels of LSF on day 0 (median, 10.88 m) compared to patients receiving 2 mg/kg (median, 7.23 m) (Figure 1 ). These LSF plasma levels were consistent with dose-proportionality data from normal patients receiving LSF in a pharmacokinetic study (unpublished data).
Engraftment
The number of days to reach an ANC у500/l was 15 days in each treatment group. There were no significant differences between treatment groups in the time to platelet recovery to у20 000/l. The median day of platelet recovery was day 14 in the placebo group, day 20 in the 2 mg/kg LSF group, and day 18 in the 3 mg/kg LSF group. Similarly, there were no significant differences between treat- ment groups in the number of transfusion events for platelets (5, placebo; 12, 2 mg/kg; and 6, 3 mg/kg) or packed red blood cells (2.5, placebo; 2.0, 2 mg/kg; and 2.0, 3 mg/kg), to day 21 or hospital discharge.
Infections
There was no significant difference in the median number of days of fever between treatment groups (range, 1-2 days). However, no patient who received LSF at 3 mg/kg developed any infections between day 0 and 35 compared with seven patients (39%) in the placebo group and eight patients (35%) in the 2 mg/kg LSF group (3 mg/kg vs placebo, P = 0.003; Table 4 ). Five patients (28%) in the placebo group and five patients (22%) in the 2 mg/kg LSF group had serious infections between day 0 and 35, while there were no serious infections in the 3 mg/kg LSF group (P = 0.015). Furthermore, no patient in the 3 mg/kg LSF group experienced a serious or fatal infection before day 100 post-BMT compared with seven placebo-treated patients (39%), who developed eight serious or fatal infections by day 100, and seven patients (30%) in the 2 mg/kg LSF group (3 mg/kg vs placebo, P = 0.003). The types of documented infections are summarized in Table 5 .
Transplant-related toxicities
No differences were observed between treatment groups in the incidence of acute renal or hepatic insufficiency. Treatment with LSF was associated with a trend toward a dosedependent reduction in the frequency and severity of mucositis. 27 All of the placebo-treated patients (100%) developed at least grade 1 mucositis, compared with 20 of 23 patients (87%) in the 2 mg/kg LSF group and 16 of 19 patients (84%) in the 3 mg/kg LSF group. Furthermore, grade 2 mucositis was reported in eight placebo-treated patients (44%), eight patients (35%) receiving 2 mg/kg LSF, and five (26%) patients receiving 3 mg/kg LSF (3 mg/kg vs placebo, P = 0.104). 
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Acute GVHD There were no significant between-group differences in the incidence of clinically significant (grade 2 to 4) acute GVHD. Grade 2 to 4 GVHD was reported in seven patients (39%) receiving placebo, 11 patients (48%) receiving 2 mg/kg LSF, and seven patients (37%) receiving 3 mg/kg LSF. However, the incidence of skin rashes occurring before day 28 (ie, shortly after hematopoietic engraftment), which are often the first clinical sign of GVHD, was significantly reduced in the 3 mg/kg LSF group compared with the placebo group. Skin rashes before day 28 were reported in 12 patients (67%) receiving placebo, compared with 10 patients (43%) receiving 2 mg/kg LSF and three patients (16%) receiving 3 mg/kg LSF (3 mg/kg vs placebo, P = 0.002).
Survival and relapse
Kaplan-Meier estimates of overall survival are shown in Figure 2 . Twenty-two deaths occurred within the first 100 days after transplantation, including seven deaths in the placebo group (excluding one patient who died on day 101), 12 deaths in the 2 mg/kg LSF group, and two deaths in the 3 mg/kg LSF group. The overall survival rate at day 100 was significantly improved in the 3 mg/kg LSF group compared with placebo (log-rank test, P = 0.026). At day 100 post-BMT, 10 (61%) patients in the placebo group were alive, compared with 11 (48%) patients receiving 2 mg/kg LSF, and 17 (89%) patients receiving 3 mg/kg LSF. Causes of death during the first 100 days post-BMT are summarized in Table 6 . With all patients followed for more than 1 year after BMT, the 1-year survival rate for the three groups was 44%, 35%, and 53% in the placebo, 2 mg/kg, and 3 mg/kg LSF groups, respectively. Three patients in each group have relapsed. Figure 3 shows survival for all patients on the basis of the number of adverse risk factors (ie, age у40 years, PS у1, and CMV seropositive) and indicates an inverse correlation between the number of risk factors and the probability of survival. When patients with two or three of these risk factors were analyzed separately, a doserelated survival benefit was observed in both LSF treatment groups. Patients in each treatment group with 0 or 1 risk factor had equivalent probability of survival.
Discussion
The principal objectives of this study were to evaluate the safety and tolerability of two dose levels of LSF administered to patients with hematologic malignancies undergoing HLA-identical, sibling-donor, allogeneic BMT, and to determine the effect of LSF on the interval to hematologic engraftment. Secondary objectives included an assessment of the impact of LSF on regimen-related toxicities, including infections, mucositis, and mortality.
LSF was well tolerated, and 75% of patients completed all intended study drug treatment. Headache and nausea, with or without vomiting, were the only reported adverse effects that appeared to be study drug-related. Eleven per- Figure 2 Cumulative probability of overall survival at day 100 by treatment arm. The number of patients alive at day 100 was significantly higher in the LSF 3 mg/kg group (89%) compared to placebo (56%) and LSF 2 mg/kg (48%) cohorts (P = 0.026). cent of LSF-treated patients reported nausea of sufficient severity to necessitate early study drug withdrawal; however, the absence of a dose-dependent increase in nausea in the LSF-treatment groups suggests that this adverse effect, if study drug related, is not dose-limiting.
Engraftment endpoints, including the time to neutrophil recovery (у500/l), platelet recovery, and blood product utilization, were not impacted by LSF treatment. The apparent lack of effect of LSF on hematopoietic reconstitution observed in this trial contrasts with the results of preclinical studies, 16, 21 and the dose-dependent acceleration of hematopoietic reconstitution seen in the phase I study. 25 The reasons for these differences are not clear; however, placebo-treated patients in the current study experienced rapid hematopoietic reconstitution, which exceeded engraftment kinetics reported in previous studies employing similar GVHD prophylaxis regimens. 31 The striking results in this study were the highly significant protection against infections and the improved day-100 survival in the 3 mg/kg LSF group, despite the lack of effect on neutrophil recovery. No patient treated with 3 mg/kg LSF developed a documented infection by day 35 or a subsequent serious or fatal infection to day 100. This benefit translated into a significant reduction in procedurerelated deaths and an improvement in overall survival at day 100 (P = 0.026). Treatment with 2 mg/kg LSF did not improve day-100 survival. This lack of survival benefit in the 2 mg/kg LSF group may relate in part to the higher proportion of poor-risk patients in this treatment group, thereby contributing to a greater risk for procedure-related morbidity and mortality. When adjusted for multiple adverse risk factors (ie, 2 or 3), treatment with 2 mg/kg LSF was associated with improved long-term survival compared with placebo ( Figure 3) .
A number of risk factors have been shown by multivariate analyses to be predictive of adverse outcome in HLAmatched, sibling-donor, allogeneic BMT. These factors include diagnosis, disease stage, age, PS, CMV exposure, and conditioning regimen. [32] [33] [34] An analysis of the current data set, based on age, PS, and CMV status, confirmed that the presence of multiple risk factors in an individual confers additive risk of mortality (Figure 3) . Although the treatment groups in this study were balanced with respect to conditioning regimens and disease stage, a greater proportion of patients in the 2 mg/kg LSF group were older (age у40 years), had a worse SWOG PS (у1), and were CMV seropositive compared with the placebo group ( Table 2) . Although the 2 mg/kg LSF group contained more patients considered to have favorable diagnoses and disease stage (eg, chronic-phase chronic myeloid leukemia and acute leukemia in first complete remission), this apparent advantage was confounded by the disparity in age, PS, and CMV status. Consequently, patients in the placebo group had more favorable clinical characteristics than those in either LSF-treatment groups, and patients in the 2 mg/kg LSF group were at the highest risk for procedure-related morbidity and mortality.
Imbalances in these risk factors may have also contributed to the apparent lack of a dose-response relationship for the major efficacy endpoints in the LSF-treated cohorts. However, when high-risk patients were analyzed separately for survival (Figure 3) , a dose-response relationship was observed, although the number of patients within each group is small. In addition, analysis of peak serum LSF levels on day 0 indicated that patients in the 2 mg/kg LSF group did not consistently achieve a minimum effective concentration (median C max ; 10 m). The rapid distribution phase for LSF makes accurate determination of the C max difficult in a clinical setting. The measured C max values may therefore underestimate the actual values. The IC 50 for LSF predicted by surrogate biologic assays was approximately 15 m.
The results of this study strongly indicate that factors in addition to the duration of neutropenia are major determinants for the occurrence of infectious events in allogeneic BMT recipients. This notion is supported by the results of prior studies involving patients undergoing dose-intensive cytotoxic therapy. For example, in patients with acute
Bone Marrow Transplantation myeloid leukemia undergoing dose-intensive chemotherapy, the degree and duration of mucosal barrier dysfunction and not the duration of neutropenia correlated with the risk of developing severe infections, particularly invasive fungal infections. 35 Donnelly et al 36 reported that the severity of mucositis correlated with the risk of streptococcal bacteremia in BMT recipients. The protective effect of LSF on mucosal barrier integrity, observed in preclinical studies, 19, 20, 37 is consistent with the reduction in the frequency of severe mucositis in the 3 mg/kg LSF-treated patients in this study.
Preclinical and preliminary clinical data suggest that LSF acts via suppression of the inflammatory response to oxidative injury, thus minimizing disruption of mucosal barriers and the translocation of microorganisms. Lisofylline has been shown to reduce the generation of HPODEs and inflammatory cytokines, and to reduce mucosal damage as a consequence of dose-intensive chemotherapy and radiation in a variety of model systems and in humans. 3, [16] [17] [18] 21, 24, 38 The reduction in mucositis and the corresponding reduction in the incidence of infections observed in the current trial is consistent with this mechanism of action.
Data from animal studies suggest that mucosal barrier protection may modulate GVHD. 10 Although there was no observed effect of LSF in the current study with regard to the frequency or severity of GVHD or other regimenrelated toxicities such as veno-occlusive disease and renal insufficiency, the imbalance in risk factors among treatment groups and the sample size limited the power to discern an impact on these events. In a companion analysis of serum samples from patients on the current study, elevated serum levels of HPODEs on day 0 were associated with subsequent development of grade 2 or greater acute GVHD and treatment-related mortality, LSF suppressed HPODE levels in a dose-dependent fashion and pre-conditioning HPODE levels correlated with clinical risk factors. 38 Consistent with the demographic features, patients in the 2 mg/kg LSF group had significantly higher baseline HPODE levels than patients in the placebo group, and patients in the 3 mg/kg LSF group had intermediate levels.
Given the protective effects of LSF on the mucosal epithelium and its effects on the production of inflammatory cytokines, it is possible that treatment with LSF may impact the development of GVHD. 10 Although we observed no difference in the frequency of grades 2 to 4 acute GVHD among the treatment groups, this study was not powered to discern a significant difference in this event.
Previous randomized trials evaluating the effects of the related methylxanthine derivative, pentoxifylline, failed to show an impact of such treatment on the frequency or severity of regimen-related toxicities or transplant-related infections. 39, 40 Although structurally similar, LSF and pentoxifylline have distinct pharmacologic properties. For example, in specific in vitro assays such as inhibition of IL-12-induced expression of IFN-␥ in T lymphocytes, LSF is active at clinically relevant concentrations of 10 to 20 m, while pentoxifylline and its S-enantiomer are inactive. 26 In the present study, treatment with 3 mg/kg LSF was well tolerated, exceeded target plasma concentrations, and significantly reduced the frequency of transplant-related infections and improved overall survival. Two larger prospective randomized, placebo-controlled trials are now in progress in patients with hematologic malignancies undergoing allogeneic BMT from HLA-identical sibling donors and HLA-matched unrelated donors. These studies are prospectively stratified by risk factors and will have sufficient sample size to evaluate the potential impact of LSF treatment (3 mg/kg) upon the development and severity of acute GVHD, regimen-related toxicities, and engraftment kinetics.
